A Phase I Study of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia

Full Title

A Phase I Trial of SGN-CD33A in Patients with CD33-positive Acute Myeloid Leukemia


The purpose of this study is to identify the highest dose of an investigational drug called SGN-CD33A that can be given safely in patients with acute myeloid leukemia (AML) that has persisted or returned despite standard therapy, or is not being treated with high-dose induction chemotherapy. SGN-CD33A has two parts: one (an antibody) that attaches to a protein called CD33 on the surface of cancer cells (including AML) and another (an anticancer drug) that kills the cancer. SGN-CD33A is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have AML that has returned despite prior therapy, or patients must have declined high-dose induction chemotherapy for AML and have received no more than one previous regimen of palliative therapy.
  • At least 2 weeks must have passed since completion of prior non-myeloablative treatment (therapy which does not destroy blood-forming cells) and 4 weeks since myeloablative therapy (high-dose induction/consolidation chemotherapy) and entry into the study.
  • Patients who previously had a stem cell transplant may not participate.
  • This study is open to patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Eytan Stein at 212-639-3314.